Therapeutic strategies to enhance the anticancer efficacy of histone deacetylase inhibitors

Journal of Biomedicine and Biotechnology

Volumn 2011, Issue , 2011, Pages

  Chandra, Joya ^a   Miller, Claudia P ^a,b   Singh, Melissa M ^a   Rivera Del Valle, Nilsa ^a,c   Manton, Christa A ^a,c  

^a UNIVERSITY OF TEXAS   (United States)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^c UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ADAPHOSTIN; AZACITIDINE; BEVACIZUMAB; BIM PROTEIN; BORTEZOMIB; CISPLATIN; CONATUMUMAB; DEATH RECEPTOR 5; DOXORUBICIN; ENTINOSTAT; FAS ANTIGEN; GEMTUZUMAB; HISTONE DEACETYLASE INHIBITOR; MOCETINOSTAT; OZOGAMICIN; PANOBINOSTAT; PCI 24781; PEMETREXED; PROTEIN BAD; PROTEIN BID; RETINOIC ACID; ROMIDEPSIN; SALINOSPORAMIDE A; TEMOZOLOMIDE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID; VORINOSTAT; ANTINEOPLASTIC AGENT; HISTONE DEACETYLASE; PROTEASOME; REACTIVE OXYGEN METABOLITE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ADVANCED CANCER; ANOREXIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BREAST TUMOR; CANCER FATIGUE; CELL CYCLE ARREST; CHRONIC MYELOID LEUKEMIA; COLORECTAL CANCER; COLORECTAL TUMOR; CUTANEOUS T CELL LYMPHOMA; DNA METHYLATION; DRUG EFFICACY; EPIGENETICS; GLIOBLASTOMA; HEAD AND NECK CANCER; HISTONE ACETYLATION; HUMAN; LEUKEMIA; LUNG NON SMALL CELL CANCER; LYMPHOMA; MELANOMA; MONOTHERAPY; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; MYELOMA; NK T CELL LYMPHOMA; NONHUMAN; OVARY TUMOR; PANCREAS CANCER; PERIPHERAL T CELL LYMPHOMA; REVIEW; SARCOMA; SQUAMOUS CELL CARCINOMA; TREATMENT RESPONSE; ADJUVANT THERAPY; DNA DAMAGE; DRUG ANTAGONISM; DRUG COMBINATION; DRUG EFFECT; GENETIC EPIGENESIS; METABOLISM; MULTIMODALITY CANCER THERAPY;

ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; DNA DAMAGE; DRUG THERAPY, COMBINATION; EPIGENESIS, GENETIC; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; PROTEASOME ENDOPEPTIDASE COMPLEX; RADIOTHERAPY, ADJUVANT; REACTIVE OXYGEN SPECIES;

EID: 80052653226     PISSN: 11107243     EISSN: 11107251     Source Type: Journal    
DOI: 10.1155/2011/514261     Document Type: Review

References (139)

1. Hong L., Schroth G. P., Matthews H. R., Yau P., Bradbury E. M., Studies of the DNA binding properties of histone H4 amino terminus. Thermal denaturation studies reveal that acetylation markedly reduces the binding constant of the H4 'tail' to DNA Journal of Biological Chemistry 1993 268 1 305 314 (Pubitemid 23021321)
2. Allfrey V. G., Faulkner R., Mirsky A. E., Acetylation and methylation of histones and their possible role in the regulation of RNA synthesis Proceedings of the National Academy of Sciences of the United States of 1964 51 786 794
3. Strahl B. D., Allis C. D., The language of covalent histone modifications Nature 2000 403 6765 41 45 (Pubitemid 30038513)
4. Gao L., Cueto M. A., Asselbergs F., Atadja P., Cloning and functional characterization of HDAC11, a novel member of the human histone deacetylase family Journal of Biological Chemistry 2002 277 28 25748 25755 (Pubitemid 34951896)
5. Imai S. I., Guarente L., Ten years of NAD-dependent SIR2 family deacetylases: implications for metabolic diseases Trends in Pharmacological Sciences 2010 31 5 212 220
6. Gu W., Roeder R. G., Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain Cell 1997 90 4 595 606 (Pubitemid 27357952)
7. Glaser K. B., Li J., Staver M. J., Wei R. Q., Albert D. H., Davidsen S. K., Role of Class I and Class II histone deacetylases in carcinoma cells using siRNA Biochemical and Biophysical Research Communications 2003 310 2 529 536 (Pubitemid 37163696)
8. Atadja P., Gao L., Kwon P., Trogani N., Walker H., Hsu M., Yeleswarapu L., Chandramouli N., Perez L., Versace R., Wu A., Sambucetti L., Lassota P., Cohen D., Bair K., Wood A., Remiszewski S., Selective growth inhibition of tumor cells by a novel histone deacetylase inhibitor, NVP-LAQ824 Cancer Research 2004 64 2 689 695 (Pubitemid 38120911)
9. Ungerstedt J. S., Sowa Y., Xu W. S., Shao Y., Dokmanovic M., Perez G., Ngo L., Holmgren A., Jiang X., Marks P. A., Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors Proceedings of the National Academy of Sciences of the United States of America 2005 102 3 673 678 (Pubitemid 40282724)
10. Nebbioso A., Clarke N., Voltz E., Germain E., Ambrosino C., Bontempo P., Alvarez R., Schiavone E. M., Ferrara F., Bresciani F., Weisz A., De Lera A. R., Gronemeyer H., Altucci L., Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells Nature Medicine 2005 11 1 77 84 (Pubitemid 40215841)
11. Johnstone R. W., Histone-deacetylase inhibitors: novel drugs for the treatment of cancer Nature Reviews Drug Discovery 2002 1 4 287 299 (Pubitemid 37361445)
12. Friend C., Scher W., Holland J. G., Sato T., Hemoglobin synthesis in murine virus-induced leukemic cells in vitro: stimulation of erythroid differentiation by dimethyl sulfoxide Proceedings of the National Academy of Sciences of the United States of America 1971 68 2 378 382
13. Yoshida M., Kijima M., Akita M., Beppu T., Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A Journal of Biological Chemistry 1990 265 28 17174 17179
14. Richon V. M., Ramsay R. G., Rifkind R. A., Marks P. A., Modulation of the c-myb, c-myc and p53 mRNA and protein levels during induced murine erythroleukemia cell differentiation Oncogene 1989 4 2 165 173 (Pubitemid 19096940)
15. Richon V. M., Emiliani S., Verdin E., Webb Y., Breslow R., Rifkind R. A., Marks P. A., A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases Proceedings of the National Academy of Sciences of the United States of America 1998 95 6 3003 3007 (Pubitemid 28135844)
16. Haggarty S. J., Koeller K. M., Wong J. C., Grozinger C. M., Schreiber S. L., Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation Proceedings of the National Academy of Sciences of the United States of America 2003 100 8 4389 4394 (Pubitemid 36457739)
17. Buggy J. J., Cao Z. A., Bass K. E., Verner E., Balasubramanian S., Liu L., Schultz B. E., Young P. R., Dalrymple S. A., CRA-024781: a novel synthetic inhibitor of histone deacetylase enzymes with antitumor activity in vitro and in vivo Molecular Cancer Therapeutics 2006 5 5 1309 1317 (Pubitemid 43881324)
18. Mariadason J. M., Corner G. A., Augenlicht L. H., Genetic reprogramming in pathways of colonic cell maturation induced by short chain fatty acids: comparison with trichostatin A, sulindac, and curcumin and implications for chemoprevention of colon cancer Cancer Research 2000 60 16 4561 4572 (Pubitemid 32103641)
19. Minucci S., Pelicci P. G., Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer Nature Reviews Cancer 2006 6 1 38 51 (Pubitemid 43054973)
20. Kwon S. H., Ahn S. H., Kim Y. K., Bae G. U., Yoon J. W., Hong S., Lee H. Y., Lee Y. W., Lee H. W., Han J. W., Apicidin, a histone deacetylase inhibitor, induces apoptosis and Fas/Fas ligand expression in human acute promyelocytic leukemia cells Journal of Biological Chemistry 2002 277 3 2073 2080 (Pubitemid 34968790)
21. Insinga A., Monestiroli S., Ronzoni S., Gelmetti V., Marchesi F., Viale A., Altucci L., Nervi C., Minucci S., Pelicci P. G., Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway Nature Medicine 2005 11 1 71 76 (Pubitemid 40215840)
22. Vrana J. A., Decker R. H., Johnson C. R., Wang Z., Jarvis W. D., Richon V. M., Ehinger M., Fisher P. B., Grant S., Induction of apoptosis in U937 human leukemia cells by suberoylanilide hydroxamic acid (SAHA) proceeds through pathways that are regulated by Bcl-2/Bcl-x(L), c-Jun, and p21(CIP1), but independent of p53 Oncogene 1999 18 50 7016 7025 (Pubitemid 30028872)
23. Zhao Y., Tan J., Zhuang L., Jiang X., Liu E. T., Yu Q., Inhibitors of histone deacetylases target the Rb-E2F1 pathway for apoptosis induction through activation of proapoptotic protein Bim Proceedings of the National Academy of Sciences of the United States of America 2005 102 44 16090 16095 (Pubitemid 41552872)
24. Ruefli A. A., Ausserlechner M. J., Bernhard D., Sutton V. R., Tainton K. M., Kofler R., Smyth M. J., Johnstone R. W., The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species Proceedings of the National Academy of Sciences of the United States of America 2001 98 19 10833 10838 (Pubitemid 32878706)
25. Rosato R. R., Almenara J. A., Maggio S. C., Coe S., Atadja P., Dent P., Grant S., Role of histone deacetylase inhibitor-induced reactive oxygen species and DNA damage in LAQ-824/fludarabine antileukemic interactions Molecular Cancer Therapeutics 2008 7 10 3285 3297
26. Gao S., Mobley A., Miller C., Boklan J., Chandra J., Potentiation of reactive oxygen species is a marker for synergistic cytotoxicity of MS-275 and 5-azacytidine in leukemic cells Leukemia Research 2008 32 5 771 780 (Pubitemid 351323931)
27. Rosato R. R., Almenara J. A., Grant S., The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21 Cancer Research 2003 63 13 3637 3645 (Pubitemid 36793047)
28. Butler L. M., Zhou X., Xu W. S., Scher H. I., Rifkind R. A., Marks P. A., Richon V. M., The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin Proceedings of the National Academy of Sciences of the United States of America 2002 99 18 11700 11705 (Pubitemid 34994462)
29. Lincoln D. T., Ali Emadi E. M., Tonissen K. F., Clarke F. M., The thioredoxin-thioredoxin reductase system: over-expression in human cancer Anticancer Research 2003 23 3 B 2425 2433 (Pubitemid 36897112)
30. Shao L. E., Diccianni M. B., Tanaka T., Gribi R., Yu A. L., Pullen J. D., Camitta B. M., Yu J., Thioredoxin expression in primary T-cell acute lymphoblastic leukemia and its therapeutic implication Cancer Research 2001 61 19 7333 7338 (Pubitemid 32946533)
31. Richon V. M., Sandhoff T. W., Rifkind R. A., Marks P. A., Histone deacetylase inhibitor selectively induces p21 expressjon and gene-associated histone acetylation Proceedings of the National Academy of Sciences of the United States of America 2000 97 18 10014 10019
32. Qiu L., Burgess A., Fairlie D. P., Leonard H., Parsons P. G., Gabrielli B. G., Histone deacetylase inhibitors trigger a G2 checkpoint in normal cells that is defective in tumor cells Molecular Biology of the Cell 2000 11 6 2069 2083 (Pubitemid 30408065)
33. Sandor V., Senderowicz A., Mertins S., Sackett D., Sausville E., Blagosklonny M. V., Bates S. E., P21-dependent G arrest with downregulation of cyclin D1 and upregulation of cyclin E by the histone deacetylase inhibitor FR901228 British Journal of Cancer 2000 83 6 817 825
34. Qian D. Z., Kato Y., Shabbeer S., Wei Y., Verheul H. M. W., Salumbides B., Sanni T., Atadja P., Pili R., Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589 Clinical Cancer Research 2006 12 2 634 642 (Pubitemid 43166159)
35. Deroanne C. F., Bonjean K., Servotte S., Devy L., Colige A., Clausse N., Blacher S., Verdin E., Foidart J. M., Nusgens B. V., Castronovo V., Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling Oncogene 2002 21 3 427 436 (Pubitemid 34123805)
36. Michaelis M., Michaelis U. R., Fleming I., Suhan T., Cinatl J., Blaheta R. A., Hoffmann K., Kotchetkov R., Busse R., Nau H., Cinatl J., Valproic acid inhibits angiogenesis in vitro and in vivo Molecular Pharmacology 2004 65 3 520 527 (Pubitemid 38264019)
37. Duvic M., Talpur R., Ni X., Zhang C., Hazarika P., Kelly C., Chiao J. H., Reilly J. F., Ricker J. L., Richon V. M., Frankel S. R., Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL) Blood 2007 109 1 31 39 (Pubitemid 46053039)
38. Modesitt S. C., Sill M., Hoffman J. S., Bender D. P., A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study Gynecologic Oncology 2008 109 2 182 186
39. Vansteenkiste J., Van Cutsem E., Dumez H., Chen C., Ricker J. L., Randolph S. S., Schffski P., Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer Investigational New Drugs 2008 26 5 483 488
40. Blumenschein G. R., Kies M. S., Papadimitrakopoulou V. A., Lu C., Kumar A. J., Ricker J. L., Chiao J. H., Chen C., Frankel S. R., Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer Investigational New Drugs 2008 26 1 81 87
41. Galanis E., Jaeckle K. A., Maurer M. J., Reid J. M., Ames M. M., Hardwick J. S., Reilly J. F., Loboda A., Nebozhyn M., Fantin V. R., Richon V. M., Scheithauer B., Giannini C., Flynn P. J., Moore D. F., Zwiebel J., Buckner J. C., Phase II trial of Vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study Journal of Clinical Oncology 2009 27 12 2052 2058
42. Luu T. H., Morgan R. J., Leong L., Lim D., McNamara M., Portnow J., Frankel P., Smith D. D., Doroshow J. H., Gandara D. R., Aparicio A., Somlo G., Wong C., A phase II trial of vorinostat (suberoylanilide hydroxamic acid) in metastatic breast cancer: a California cancer consortium study Clinical Cancer Research 2008 14 21 7138 7142
43. Woyach J. A., Kloos R. T., Ringel M. D., Arbogast D., Collamore M., Zwiebel J. A., Grever M., Villalona-Calero M., Shah M. H., Lack of therapeutic effect of the histone deacetylase inhibitor vorinostat in patients with metastatic radioiodine-refractory thyroid carcinoma Journal of Clinical Endocrinology and Metabolism 2009 94 1 164 170
44. Ma X., Ezzeldin H. H., Diasio R. B., Histone deacetylase inhibitors: current status and overview of recent clinical trials Drugs 2009 69 14 1911 1934
45. Gojo I., Jiemjit A., Trepel J. B., Sparreboom A., Figg W. D., Rollins S., Tidwell M. L., Greer J., Eun J. C., Lee M. J., Gore S. D., Sausville E. A., Zwiebel J., Karp J. E., Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias Blood 2007 109 7 2781 2790 (Pubitemid 46482071)
46. Ryan Q. C., Headlee D., Acharya M., Sparreboom A., Trepel J. B., Ye J., Figg W. D., Hwang K., Chung E. J., Murgo A., Melillo G., Elsayed Y., Monga M., Kalnitskiy M., Zwiebel J., Sausville E. A., Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma Journal of Clinical Oncology 2005 23 17 3912 3922 (Pubitemid 46218694)
47. Kummar S., Gutierrez M., Gardner E. R., Donovan E., Hwang K., Eun J. C., Lee M. J., Maynard K., Kalnitskiy M., Chen A., Melillo G., Ryan Q. C., Conley B., Figg W. D., Trepel J. B., Zwiebel J., Doroshow J. H., Murgo A. J., Phase I trial of MS-275, a histone deacetylase inhibitor, administered weekly in refractory solid tumors and lymphoid malignancies Clinical Cancer Research 2007 13 18 5411 5417 (Pubitemid 47510368)
48. Gore L., Rothenberg M. L., O'Bryant C. L., Schultz M. K., Sandler A. B., Coffin D., McCoy C., Schott A., Scholz C., Eckhardt S. G., A phase I and pharmacokinetic study of the oral histone deacetylase inhibitor, MS-275, in patients with refractory solid tumors and lymphomas Clinical Cancer Research 2008 14 14 4517 4525
49. O'Connor O. A., Heaney M. L., Schwartz L., Richardson S., Willim R., MacGregor-Cortelli B., Curly T., Moskowitz C., Portlock C., Horwitz S., Zelenetz A. D., Frankel S., Richon V., Marks P., Kelly W. K., Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies Journal of Clinical Oncology 2006 24 1 166 173 (Pubitemid 46630509)
50. Kelly W. K., O'Connor O. A., Krug L. M., Chiao J. H., Heaney M., Curley T., MacGregore-Cortelli B., Tong W., Secrist J. P., Schwartz L., Richardson S., Chu E., Olgac S., Marks P. A., Scher H., Richon V. M., Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer Journal of Clinical Oncology 2005 23 17 3923 3931 (Pubitemid 46218695)
51. Choudhary C., Kumar C., Gnad F., Nielsen M. L., Rehman M., Walther T. C., Olsen J. V., Mann M., Lysine acetylation targets protein complexes and co-regulates major cellular functions Science 2009 325 5942 834 840
52. Bird A., DNA methylation patterns and epigenetic memory Genes and Development 2002 16 1 6 21 (Pubitemid 34049633)
53. Tate P. H., Bird A. P., Effects of DNA methylation on DNA-binding proteins and gene expression Current Opinion in Genetics and Development 1993 3 2 226 231 (Pubitemid 23108662)
54. Meehan R. R., Lewis J. D., McKay S., Kleiner E. L., Bird A. P., Identification of a mammalian protein that binds specifically to DNA containing methylated CpGs Cell 1989 58 3 499 507 (Pubitemid 19203534)
55. Hendrich B., Bird A., Identification and characterization of a family of mammalian methyl-CpG binding proteins Molecular and Cellular Biology 1998 18 11 6538 6547 (Pubitemid 28500543)
56. Jones P. L., Veenstra G. J. C., Wade P. A., Vermaak D., Kass S. U., Landsberger N., Strouboulis J., Wolffe A. P., Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription Nature Genetics 1998 19 2 187 191 (Pubitemid 28248804)
57. Nan X., Ng H. H., Johnson C. A., Laherty C. D., Turner B. M., Eisenman R. N., Bird A., Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex Nature 1998 393 6683 386 389 (Pubitemid 28269714)
58. Dobrovic A., Simpfendorfer D., Methylation of the BRCA1 gene in sporadic breast cancer Cancer Research 1997 57 16 3347 3350 (Pubitemid 27355472)
59. Greger V., Passarge E., Hopping W., Messmer E., Horsthemke B., Epigenetic changes may contribute to the formation and spontaneous regression of retinoblastoma Human Genetics 1989 83 2 155 158 (Pubitemid 19234564)
60. Esteller M., Hamilton S. R., Burger P. C., Baylin S. B., Herman J. G., Inactivation of the DNA repair gene O(6)-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia Cancer Research 1999 59 4 793 797 (Pubitemid 29086728)
61. Ding LI., Qiu L., Zhang J., Guo B., Camptothecin-induced cell proliferation inhibition and apoptosis enhanced by DNA methyltransferase inhibitor, 5-aza-2′-deoxycytidine Biological and Pharmaceutical Bulletin 2009 32 6 1105 1108
62. Merlo A., Herman J. G., Mao L., Lee D. J., Gabrielson E., Burger P. C., Baylin S. B., Sidransky D., 5' CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers Nature Medicine 1995 1 7 686 692
63. Deng G., Chen A., Hong J., Chae H. S., Kim Y. S., Methylation of CpG in a small region of the hMLH1 promoter invariably correlates with the absence of gene expression Cancer Research 1999 59 9 2029 2033 (Pubitemid 29217657)
64. Gius D., Cui H., Bradbury C. M., Cook J., Smart D. K., Zhao S., Young L., Brandenburg S. A., Hu Y., Bisht K. S., Ho A. S., Mattson D., Sun L., Munson P. J., Chuang E. Y., Mitchell J. B., Feinberg A. P., Distinct effects on gene expression of chemical and genetic manipulation of the cancer epigenome revealed by a multimodality approach Cancer Cell 2004 6 4 361 371 (Pubitemid 39361437)
65. Walton T. J., Li G., Seth R., McArdle S. E., Bishop M. C., Rees R. C., DNA demethylation and histone deacetylation inhibition co-operate to re-express estrogen receptor beta and induce apoptosis in prostate cancer cell-lines Prostate 2008 68 2 210 222 (Pubitemid 351186233)
66. Cecconi D., Donadelli M., Pozza E. D., Rinalducci S., Zolla L., Scupoli M. T., Righetti P. G., Scarpa A., Palmieri M., Synergistic effect of trichostatin A and 5-aza-2'-deoxycytidine on growth inhibition of pancreatic endocrine tumour cell lines: a proteomic study Proteomics 2009 9 7 1952 1966
67. Klisovic M. I., Maghraby E. A., Parthun M. R., Guimond M., Sklenar A. R., Whitman S. P., Chan K. K., Murphy T., Anon J., Archer K. J., Rush L. J., Plass C., Grever M. R., Byrd J. C., Marcucci G., Depsipeptide (FR 901228) promotes histone acetylation, gene transcription, apoptosis and its activity is enhanced by DNA methyltransferase inhibitors in AML1/ETO-positive leukemic cells Leukemia 2003 17 2 350 358 (Pubitemid 36266913)
68. Chai G., Li L., Zhou W., Wu L., Zhao Y., Wang D., Lu S., Yu YU., Wang H., McNutt M. A., Hu YE. G., Chen Y., Yang Y., Wu X., Otterson G. A., Zhu W. G., HDAC inhibitors act with 5-aza-2′-deoxycytidine to inhibit cell proliferation by suppressing removal of incorporated abases in lung cancer cells PLoS One 2008 3 6
69. Rudek M. A., Zhao M., He P., Hartke C., Gilbert J., Gore S. D., Carducci M. A., Baker S. D., Pharmacokinetics of 5-azacitidine administered with phenylbutyrate in patients with refractory solid tumors or hematologic malignancies Journal of Clinical Oncology 2005 23 17 3906 3911 (Pubitemid 46218693)
70. Griffiths E. A., Gore S. D., DNA methyltransferase and histone deacetylase inhibitors in the treatment of myelodysplastic syndromes Seminars in Hematology 2008 45 1 23 30
71. Shi Y., Lan F., Matson C., Mulligan P., Whetstine J. R., Cole P. A., Casero R. A., Shi Y., Histone demethylation mediated by the nuclear amine oxidase homolog LSD1 Cell 2004 119 7 941 953 (Pubitemid 40037608)
72. Tsukada Y. I., Fang J., Erdjument-Bromage H., Warren M. E., Borchers C. H., Tempst P., Zhang YI., Histone demethylation by a family of JmjC domain-containing proteins Nature 2006 439 7078 811 816 (Pubitemid 43255695)
73. Gray S. G., Iglesias A. H., Lizcano F., Villanueva R., Camelo S., Jingu H., Teh B. T., Koibuchi N., Chin W. W., Kokkotou E., Dangond F., Functional characterization of JMJD2A, a histone deacetylase- and retinoblastoma-binding protein Journal of Biological Chemistry 2005 280 31 28507 28518 (Pubitemid 41105751)
74. Lee M. G., Wynder C., Bochar D. A., Hakimi M. A., Cooch N., Shiekhattar R., Functional interplay between histone demethylase and deacetylase enzymes Molecular and Cellular Biology 2006 26 17 6395 6402 (Pubitemid 44277880)
75. Schmidt D. M. Z., McCafferty D. G., trans-2-phenylcyclopropylamine is a mechanism-based inactivator of the histone demethylase LSD1 Biochemistry 2007 46 14 4408 4416 (Pubitemid 46559406)
76. Culhane J. C., Szewczuk L. M., Liu X., Da G., Marmorstein R., Cole P. A., A mechanism-based inactivator for histone demethylase LSD1 Journal of the American Chemical Society 2006 128 14 4536 4537
77. Gooden D. M., Schmidt D. M. Z., Pollock J. A., Kabadi A. M., McCafferty D. G., Facile synthesis of substituted trans-2-arylcyclopropylamine inhibitors of the human histone demethylase LSD1 and monoamine oxidases A and B Bioorganic and Medicinal Chemistry Letters 2008 18 10 3047 3051 (Pubitemid 351680392)
78. Lee M. G., Wynder C., Schmidt D. M., McCafferty D. G., Shiekhattar R., Histone H3 lysine 4 demethylation is a target of nonselective antidepressive medications Chemistry and Biology 2006 13 6 563 567
79. Yang M., Culhane J. C., Szewczuk L. M., Jalili P., Ball H. L., Machius M., Cole P. A., Yu H., Structural basis for the inhibition of the LSD1 histone demethylase by the antidepressant trans-2-phenylcyclopropylamine Biochemistry 2007 46 27 8058 8065 (Pubitemid 47051641)
80. Singh M. M., Manton C. A., Bhat K. P., Inhibition of LSD1 sensitizes glioblastoma cells to histone deacetylase inhibitors. Neuro-Oncology. In press
81. Wang J., Hevi S., Kurash J. K., Lei H., Gay F., Bajko J., Su H., Sun W., Chang H., Xu G., Gaudet F., Li EN., Chen T., The lysine demethylase LSD1 (KDM1) is required for maintenance of global DNA methylation Nature Genetics 2009 41 1 125 129
82. Ciccone D. N., Su H., Hevi S., Gay F., Lei H., Bajko J., Xu G., Li EN., Chen T., KDM1B is a histone H3K4 demethylase required to establish maternal genomic imprints Nature 2009 461 7262 415 418
83. Huang Y., Stewart T. M., Wu Y., Baylin S. B., Marton L. J., Perkins B., Jones R. J., Woster P. M., Casero R. A., Novel oligoamine analogues inhibit lysine-specific demethylase 1 and induce reexpression of epigenetically silenced genes Clinical Cancer Research 2009 15 23 7217 7228
84. Sakurai M., Rose N. R., Schultz L., Quinn A. M., Jadhav A., Ng S. S., Oppermann U., Schofield C. J., Simeonov A., A miniaturized screen for inhibitors of Jumonji histone demethylases Molecular BioSystems 2010 6 2 357 364
85. Chandra J., Oxidative Stress by targeted agents promotes cytotoxicity in hematologic malignancies Antioxidants and Redox Signaling 2009 11 5 1123 1127
86. Pelicano H., Carney D., Huang P., ROS stress in cancer cells and therapeutic implications Drug Resistance Updates 2004 7 2 97 110 (Pubitemid 38736063)
87. Toyokuni S., Oxidative stress and cancer: the role of redox regulation Biotherapy 1998 11 2-3 147 154 (Pubitemid 28284927)
88. Kaur G., Narayanan V. L., Risbood P. A., Hollingshead M. G., Stinson S. F., Varma R. K., Sausville E. A., Synthesis, structure-activity relationship, and p210 protein tyrosine kinase activity of novel AG 957 analogs Bioorganic and Medicinal Chemistry 2005 13 5 1749 1761 (Pubitemid 40215261)
89. Chandra J., Tracy J., Loegering D., Flatten K., Verstovsek S., Beran M., Gorre M., Estrov Z., Donato N., Talpaz M., Sawyers C., Bhalla K., Karp J., Sausville E., Kaufmann S. H., Adaphostin-induced oxidative stress overcomes BCR/ABL mutation-dependent and -independent imatinib resistance Blood 2006 107 6 2501 2506 (Pubitemid 43345574)
90. Chandra J., Hackbarth J., Le S., Loegering D., Bone N., Bruzek L. M., Narayanan V. L., Adjei A. A., Kay N. E., Tefferi A., Karp J. E., Sausville E. A., Kaufmann S. H., Involvement of reactive oxygen species in adaphostin-induced cytotoxicity in human leukemia cells Blood 2003 102 13 4512 4519 (Pubitemid 37494118)
91. Le S. B., Hailer M. K., Buhrow S., Wang QI., Flatten K., Pediaditakis P., Bible K. C., Lewis L. D., Sausville E. A., Pang Y. P., Ames M. M., Lemasters J. J., Holmuhamedov E. L., Kaufmann S. H., Inhibition of mitochondrial respiration as a source of adaphostin-induced reactive oxygen species and cytotoxicity Journal of Biological Chemistry 2007 282 12 8860 8872 (Pubitemid 47093495)
92. Stockwin L. H., Bumke M. A., Yu S. X., Webb S. P., Collins J. R., Hollingshead M. G., Newton D. L., Proteomic analysis identifies oxidative stress induction by adaphostin Clinical Cancer Research 2007 13 12 3667 3681 (Pubitemid 46955131)
93. Cheung K. L., Kong A. N., Molecular targets of dietary phenethyl isothiocyanate and sulforaphane for cancer chemoprevention AAPS Journal 2010 12 1 87 97
94. Xiao D., Jonhson C. S., Trump D. L., Singh S. V., Proteasome-mediated degradation of cell division cycle 25C and cyclin-dependent kinase 1 in phenethyl isothiocyanate-induced G-M-phase cell cycle arrest in PC-3 human prostate cancer cells Molecular Cancer Therapeutics 2004 3 5 567 575 (Pubitemid 39193735)
95. Beklemisheva A. A., Feng J., Yeh Y. A., Wang L. G., Chiao J. W., Modulating testosterone stimulated prostate growth by phenethyl isothiocyanate via Sp1 and androgen receptor down-regulation Prostate 2007 67 8 863 870 (Pubitemid 46828940)
96. Xiao D., Powolny A. A., Moura M. B., Kelley E. E., Bommareddy A., Kim S. -H., Hahm E. -R., Normolle D., Van Houten B., Singh S. V., Phenethyl isothiocyanate inhibits oxidative phosphorylation to trigger reactive oxygen species-mediated death of human prostate cancer cells Journal of Biological Chemistry 2010 285 34 26558 26569
97. Trachootham D., Zhou Y., Zhang H., Demizu Y., Chen Z., Pelicano H., Chiao P. J., Achanta G., Arlinghaus R. B., Liu J., Huang P., Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by -phenylethyl isothiocyanate Cancer Cell 2006 10 3 241 252 (Pubitemid 44311067)
98. Trachootham D., Zhang H., Zhang W., Feng LI., Du M., Zhou Y., Chen Z., Pelicano H., Plunkett W., Wierda W. G., Keating M. J., Huang P., Effective elimination of fludarabine-resistant CLL cells by PEITC through a redox-mediated mechanism Blood 2008 112 5 1912 1922
99. Hu Y., Lu W., Chen G., Zhang H., Jia Y., Wei Y., Yang H., Zhang W., Fiskus W., Bhalla K., Keating M., Huang P., Garcia-Manero G., Overcoming resistance to histone deacetylase inhibitors in human leukemia with the redox modulating compound -phenylethyl isothiocyanate Blood 2010 116 15 2732 2741
100. Orlowski M., Wilk S., Catalytic activities of the 20 S proteasome, a multicatalytic proteinase complex Archives of Biochemistry and Biophysics 2000 383 1 1 16
101. Masdehors P., Omura S., Merle-Beral H., Mentz F., Cosset J. M., Dumont J., Magdelénat H., Delic J., Increased sensitivity of CLL-derived lymphocytes to apoptotic death activation by the proteasome-specific inhibitor lactacystin British Journal of Haematology 1999 105 3 752 757 (Pubitemid 29277035)
102. Drexler H. C. A., Activation of the cell death program by inhibition of proteasome function Proceedings of the National Academy of Sciences of the United States of America 1997 94 3 855 860 (Pubitemid 27074411)
103. Pei X. Y., Dai Y., Grant S., Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors Clinical Cancer Research 2004 10 11 3839 3852 (Pubitemid 38697620)
104. Yu C., Rahmani M., Conrad D., Subler M., Dent P., Grant S., The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl cells sensitive and resistant to STI571 Blood 2003 102 10 3765 3774 (Pubitemid 37409399)
105. Feng R., Oton A., Mapara M. Y., Anderson G., Belani C., Lentzsch S., The histone deacetylase inhibitor, PXD101, potentiates bortezomib-induced anti-multiple myeloma effect by induction of oxidative stress and DNA damage British Journal of Haematology 2007 139 3 385 397 (Pubitemid 47512171)
106. Bhalla S., Balasubramanian S., David K., Sirisawad M., Buggy J., Mauro L., Prachand S., Miller R., Gordon L. I., Evens A. M., PCI-24781 induces caspase and reactive oxygen species-dependent apoptosis through NF- B mechanisms and is synergistic with bortezomib in lymphoma cells Clinical Cancer Research 2009 15 10 3354 3365
107. Ling Y. H., Liebes L., Zou Y., Perez-Soler R., Reactive oxygen species generation and mitochondrial dysfunction in the apoptotic response to Bortezomib, a novel proteasome inhibitor, in human H460 non-small cell lung cancer cells Journal of Biological Chemistry 2003 278 36 33714 33723 (Pubitemid 37553204)
108. Nawrocki S. T., Carew J. S., Pino M. S., Highshaw R. A., Andtbacka R. H. I., Dunner K., Pal A., Bornmann W. G., Chiao P. J., Huang P., Xiong H., Abbruzzese J. L., McConkey D. J., Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells Cancer Research 2006 66 7 3773 3781
109. Hideshima T., Bradner J. E., Wong J., Chauhan D., Richardson P., Schreiber S. L., Anderson K. C., Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma Proceedings of the National Academy of Sciences of the United States of America 2005 102 24 8567 8572 (Pubitemid 40862776)
110. Chauhan D., Catley L., Li G., Podar K., Hideshima T., Velankar M., Mitsiades C., Mitsiades N., Yasui H., Letai A., Ovaa H., Berkers C., Nicholson B., Chao TA. H., Neuteboom S. T. C., Richardson P., Palladino M. A., Anderson K. C., A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib Cancer Cell 2005 8 5 407 419 (Pubitemid 41579835)
111. Ruiz S., Krupnik Y., Keating M., Chandra J., Palladino M., McConkey D., The proteasome inhibitor NPI-0052 is a more effective inducer of apoptosis than bortezomib in lymphocytes from patients with chronic lymphocytic leukemia Molecular Cancer Therapeutics 2006 5 7 1836 1843 (Pubitemid 44323252)
112. Cusack J. C., Liu R., Xia L., Chao TA. H., Pien C., Niu W., Palombella V. J., Neuteboom S. T. C., Palladino M. A., NPI-0052 enhances tumoricidal response to conventional cancer therapy in a colon cancer model Clinical Cancer Research 2006 12 22 6758 6764 (Pubitemid 44876845)
113. Miller C. P., Ban K., Dujka M. E., McConkey D. J., Munsell M., Palladino M., Chandra J., NPI-0052, a novel proteasome inhibitor, induces caspase-8 and ROS-dependent apoptosis alone and in combination with HDAC inhibitors in leukemia cells Blood 2007 110 1 267 277 (Pubitemid 47026844)
114. Roccaro A. M., Leleu X., Sacco A., Jia X., Melhem M., Moreau A. S., Ngo H. T., Runnels J., Azab A., Azab F., Burwick N., Farag M., Treon S. P., Palladino M. A., Hideshima T., Chauhan D., Anderson K. C., Ghobrial I. M., Dual targeting of the proteasome regulates survival and homing in Waldenstrm macroglobulinemia Blood 2008 111 9 4752 4763
115. Miller C. P., Rudra S., Keating M. J., Wierda W. G., Palladino M., Chandra J., Caspase-8 dependent histone acetylation by a novel proteasome inhibitor, NPI-0052: a mechanism for synergy in leukemia cells Blood 2009 113 18 4289 4299
116. Kikuchi J., Wada T., Shimizu R., Izumi T., Akutsu M., Mitsunaga K., Noborio-Hatano K., Nobuyoshi M., Ozawa K., Kano Y., Furukawa Y., Histone deacetylases are critical targets of bortezomib-induced cytotoxicity in multiple myeloma Blood 2010 116 3 406 417
117. O'Connor O. A., Stewart A. K., Vallone M., Molineaux C. J., Kunkel L. A., Gerecitano J. F., Orlowski R. Z., A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies Clinical Cancer Research 2009 15 22 7085 7091
118. Kuhn D. J., Chen Q., Voorhees P. M., Strader J. S., Shenk K. D., Sun C. M., Demo S. D., Bennett M. K., Van Leeuwen F. W. B., Chanan-Khan A. A., Orlowski R. Z., Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma Blood 2007 110 9 3281 3290 (Pubitemid 350106321)
119. Dasmahapatra G., Lembersky D., Kramer L., Fisher R. I., Friedberg J., Dent P., Grant S., The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivo Blood 2010 115 22 4478 4487
120. Chen X., Wong P., Radany E., Wong J. Y. C., HDAC inhibitor, valproic acid, induces p53-dependent radiosensitization of colon cancer cells Cancer Biotherapy and Radiopharmaceuticals 2009 24 6 689 699
121. Geng L., Cuneo K. C., Fu A., Tu T., Atadja P. W., Hallahan D. E., Histone deacetylase (HDAC) inhibitor LBH589 increases duration of -H2AX foci and confines HDAC4 to the cytoplasm in irradiated non-small cell lung cancer Cancer Research 2006 66 23 11298 11304 (Pubitemid 46009960)
122. Venkitaraman A. R., Modifying chromatin architecture during the response to DNA breakage Critical Reviews in Biochemistry and Molecular Biology 2010 45 1 2 13
123. Zhang Y., Adachi M., Kawamura R., Zou H. C., Imai K., Hareyama M., Shinomura Y., Bmf contributes to histone deacetylase inhibitor-mediated enhancing effects on apoptosis after ionizing radiation Apoptosis 2006 11 8 1349 1357 (Pubitemid 44035946)
124. Camphausen K., Cerna D., Scott T., Sproull M., Burgan W. E., Cerra M. A., Fine H., Tofilon P. J., Enhancement of in vitro and in vivo tumor cell radiosensitivity by valproic acid International Journal of Cancer 2005 114 3 380 386 (Pubitemid 40279957)
125. Zhang F., Zhang T., Teng Z.-H., Zhang R., Wang J.-B., Mei Q.-B., Sensitization to -irradiation-induced cell cycle arrest and apoptosis by the histone deacetylase inhibitor trichostatin A in non-small cell lung cancer (NSCLC) cells Cancer Biology and Therapy 2009 8 9 823 831
126. Kumar K. S., Sonnemann J., Hong L. T. T., Buurman C., Adler F., Maass M., Vlker U., Beck J. F., Histone deacetylase inhibitors, but not vincristine, cooperate with radiotherapy to induce cell death in medulloblastoma Anticancer Research 2007 27 1 A 465 470 (Pubitemid 46363367)
127. Zhang Y., Adachi M., Zhao X., Kawamura R., Imai K., Histone deacetylase inhibitors FK228, N-(2-aminophenyl)-4-[N-(pyridin-3-yl-methoxycarbonyl)amino- methyl]benzamide and m-carboxycinnamic acid bis-hydroxamide augment radiation-induced cell death in gastrointestinal adenocarcinoma cells International Journal of Cancer 2004 110 2 301 308 (Pubitemid 38580407)
128. Banuelos C. A., Banth J. P., MacPhail S. H., Zhao J., Reitsema T., Olive P. L., Radiosensitization by the histone deacetylase inhibitor PCI-24781 Clinical Cancer Research 2007 13 22 6816 6826 (Pubitemid 350206820)
129. Munshi A., Tanaka T., Hobbs M. L., Tucker S. L., Richon V. M., Meyn R. E., Vorinostat, a histone deacetylase inhibitor, enhances the response of human tumor cells to ionizing radiation through prolongation of -H2AX foci Molecular Cancer Therapeutics 2006 5 8 1967 1974 (Pubitemid 44336568)
130. Camphausen K., Scott T., Sproull M., Tofilon P. J., Enhancement of xenograft tumor radiosensitivity by the histone deacetylase inhibitor MS-275 and correlation with histone hyperacetylation Clinical Cancer Research 2004 10 18 I 6066 6071 (Pubitemid 39302609)
131. Kim I. A., Shin J. H., Kim I. H., Kim J. H., Kim J. S., Wu H. G., Chie E. K., Ha S. W., Park C., Kao G. D., Histone deacetylase inhibitor-mediated radiosensitization of human cancer cells: class differences and the potential influence of p53 Clinical Cancer Research 2006 12 3 I 940 949 (Pubitemid 43259877)
132. Kim M. S., Blake M., Baek J. H., Kohlhagen G., Pommier Y., Carrier F., Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA Cancer Research 2003 63 21 7291 7300 (Pubitemid 37413470)
133. Stupp R., Mason W. P., Van Den Bent M. J., Weller M., Fisher B., Taphoorn M. J. B., Belanger K., Brandes A. A., Marosi C., Bogdahn U., Curschmann J., Janzer R. C., Ludwin S. K., Gorlia T., Allgeier A., Lacombe D., Cairncross J. G., Eisenhauer E., Mirimanoff R. O., Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma New England Journal of Medicine 2005 352 10 987 996 (Pubitemid 40349501)
134. Entin-Meer M., Yang X., VandenBerg S. R., Lamborn K. R., Nudelman A., Rephaeli A., Haas-Kogan D. A., In vivo efficacy of a novel histone deacetylase inhibitor in combination with radiation for the treatment of gliomas Neuro-Oncology 2007 9 2 82 88 (Pubitemid 46580309)
135. Siegel D., Hussein M., Belani C., Robert F., Galanis E., Richon V. M., Garcia-Vargas J., Sanz-Rodriguez C., Rizvi S., Vorinostat in solid and hematologic malignancies Journal of Hematology and Oncology 2009 2, article no. 31
136. Dimopoulos M. A., San-Miguel J. F., Anderson K. C., Emerging therapies for the treatment of relapsed or refractory multiple myeloma European Journal of Haematology 2011 86 1 1 15
137. Silverman L. R., Verma A., Odchimar-Reissig R., A phase I trial of the epigenetic modulators vorinostat, in combination with azacitidine (azaC) in patients with the Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML): a study of the New York Cancer Consortium ASH Annual Meeting Abstracts 2008 112 11 3656
138. Gore S. D., Jiemjit A., Silverman L. B., Combined methyltransferase/ histone deacetylase inhibition with 5-azacitidine and ms-275 in patients with MDS, CMMoL and AML: clinical response, histone acetylation and DNA damage ASH Annual Meeting Abstracts 2006 108 11 517
139. Johnstone R. W., Licht J. D., Histone deacetylase inhibitors in cancer therapy: is transcription the primary target? Cancer Cell 2003 4 1 13 18 (Pubitemid 36904157)